Sarcoma Flashcards Preview

Surgical Oncology > Sarcoma > Flashcards

Flashcards in Sarcoma Deck (11)
1

desmin is a marker for

myogenic differentiation:
RMS
leiomyosarcoma

2

sarcomas are what percent of adult and pediatric tumors?

1% adult
13% pediatric

3

s100 antigen suggests:

melanocytic differentiation
clear cell carcinoma
neural sheath tumors

4

Potential molecular markers of sarcoma?

numerous well described chromosomal translocations. Think T11:22 in Ewings

5

SMAC meta-analysis of adjuvant therapy for sarcoma?

Significant local RFS, distant RFS, overall RFS, but not for overall survival (HR 0.89 CI 0.76-1.03)

More benefit for trunkal/limb sarcomas where DOX had 7% absolute overall survival benefit at 10 years.

6

Response rate of metastatic STS to single agent chemo

20% for doxorubicin, epirubicin and ifosfamide

PMID 7490240

7

most chemo-sensitive subtypes of STS?

Synovial sarcomas and myxoid/round cell liposarcomas

8

Do GISTs respond to standard chemotherapy?

No

9

Additional class of chemo angiosarcomas are sensitive to?

taxanes (paclitaxel) but unclear if this is superior to doxorubicin/ifosfamide.

10

Potential first line targeted therapy for STS (combined with Dox)

Olaratumab - PDGFR-alpha blocker.
FDA approved 1st line after PHASE II trial. (26.5 v 14.7 mo OS and allowed crossover)
Phase III is Announce - completes in 2020

11

ASCO abstracts for Immunotherapy for STS

Alliance A091401 - Nivo/chemo had 6/38 response 16% http://abstracts.asco.org/199/AbstView_199_184079.html

SARC028 - pembro monotherapy - 40% response for pleomorphic sarcoma; 20% for liposarcoma. (expansion studies underway) http://abstracts.asco.org/199/AbstView_199_192958.html